Related Experiment Video
Updated: Jan 9, 2026

Surgical Treatment of an Endolymphatic Sac Tumor
Published on: May 26, 2023
Prognostic Value of Initial Hearing Severity in Otitis Media With Antineutrophil Cytoplasmic Antibody-Associated
Kazuki Nakada1, Koji Takii1, Nao Koide2
1Department of Otolaryngology Head and Neck Surgery, Toyama University Faculty of Medicine, Toyama.
Objective:
To identify prognostic factors for hearing outcomes in patients with otitis media with ANCA-associated vasculitis (OMAAV).
Study Design:
Retrospective cohort study.
Setting:
Tertiary referral center.
Patients:
A total of 45 ears from 24 patients with OMAAV were followed up for more than 1 year after treatment.
Interventions:
Corticosteroids with or without immunosuppressive agents.
Main Outcome Measures:
The final hearing outcome was defined as good (≤30 dB) or poor (>30 dB) based on the average air conduction at 5 frequencies. Potential prognostic factors were analyzed by constructing a receiver operating characteristic (ROC) curve, followed by multivariate logistic regression analysis.
Results:
The mean hearing level before treatment was 62.5 dB. Twelve ears (26.7%) achieved a final hearing of ≤30 dB. Multivariate logistic regression analysis revealed that the pretreatment air-conduction threshold was significantly associated with good hearing outcomes (OR = 33.6, P = 0.005). The area under the ROC curve for pretreatment hearing level was 0.946, demonstrating high accuracy. The cutoff value set at 50 dB had the best combination of sensitivity (91.7%) and specificity (84.8%) for predicting good hearing outcomes. Other variables, including C-reactive protein level, age, systemic involvement of ANCA-associated vasculitis, and treatment intensity, were not significant predictors.
Conclusions:
Pretreatment hearing level is a powerful predictor of the final auditory outcome in OMAAV. Early diagnosis and prompt initiation of treatment may improve long-term hearing prognosis. The hearing level, rather than the systemic involvement of the disease, should be prioritized when determining the therapeutic intensity.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Mitral Stenosis II: Clinical features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

